A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

NCT07133828 | Recruiting Phase 1 FDA Drug

• 1 other identifier: 300HV101
• Study Type: interventional
• Target: 78
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, researchers will learn more about the safety of BIIB142 and how it is processed in the body. This is the first time that researchers will learn about BIIB142 and how it affects people. The main question researchers want to answer in this study is:

• How many participants have adverse events (AEs) and serious adverse events (SAEs)? An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. Researchers will also learn more about:
• How the body processes BIIB142 This is a "dose escalation study." This is a study in which increasing amounts of the study drug are given to different groups of participants. This is done until researchers find the highest dose that does not cause harmful effects. First, participants will be screened to check if they can join the study. The screening period will be up to 28 days. This study will be split into 2 parts - Part A and Part B. During Part A:
• Participants will be randomly placed into 1 of 6 groups to receive a single dose of either BIIB142 or a placebo. A placebo looks like the study drug but contains no real medicine.
• Participants in Groups 1 through 5 will take either BIIB142 or the placebo without food. Participants in Group 6 will take 2 doses of their assigned treatment - once with food and once without food.
• Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
• Participants will stay at their study research center for 5 days. They will return for another 4 visits. Each participant in Part A will be in the study for up to 58 days. During Part B:
• Participants will be randomly placed into 1 of 3 groups to receive BIIB142 or the placebo. In Part B, participants will take BIIB142 or the placebo once a day for 14 days.
• Neither the researchers nor the participants will know if the participants will receive BIIB142 or the placebo.
• Participants will stay at their study research center for 16 days. They will return for another 4 visits. Each participant in Part B will be in the study for up to 58 days.

Conditions

Healthy Volunteer

Outcome Measures

Primary Outcomes (5)

• Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

• Number of Participants with Clinical Laboratory Abnormalities

  Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

• Number of Participants with Potentially Clinically Relevant Abnormalities in Vital Sign Parameters

  Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

• Number of Participants With Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score

  Part B (MAD): Up to Day 29

• Number of Participants With Potentially Clinically Relevant Abnormalities in 12-lead Electrocardiogram (ECG) Parameters

  Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29

Secondary Outcomes (7)

• Plasma Concentration of BIIB142

  Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

• Area Under the Concentration-Time Curve (AUC) of BIIB142

  Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

• Maximum Observed Concentration (Cmax) of BIIB142

  Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

• Time to Maximum Observed Concentration (Tmax) of BIIB142

  Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

• Apparent Clearance (CL/F) of BIIB142

  Pre-dose and at multiple timepoints post-dose [Part A (SAD): Up to Day 15; Part B (MAD): Up to Day 29]

Study Arms (9)

Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A

EXPERIMENTAL

Participants will receive Dose A of BIIB142 or a matching placebo on Day 1 in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part A (SAD): BIIB142 Cohort 2A

EXPERIMENTAL

Participants will receive Dose B of BIIB142 or a matching placebo on Day 1 in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part A (SAD): BIIB142 Cohort 3A

EXPERIMENTAL

Participants will receive Dose C of BIIB142 or a matching placebo on Day 1 in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part A (SAD): BIIB142 Cohort 4A

EXPERIMENTAL

Participants will receive Dose D of BIIB142 or a matching placebo on Day 1 in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part A (SAD): BIIB142 Cohort 5A

EXPERIMENTAL

Participants will receive Dose E of BIIB142 or a matching placebo on Day 1 in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part A (SAD): BIIB142 Cohort 6A

EXPERIMENTAL

Participants will receive BIIB142 on Day 1 in the fasted followed by fed state in the first sequence, and vice versa in the second sequence. A washout period of 14 days will be maintained between both the sequences. Dose will be determined based on emerging PK data.

Drug: BIIB142

Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B

EXPERIMENTAL

Participants will receive Dose A of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part B (MAD): BIIB142 Cohort 2B

EXPERIMENTAL

Participants will receive Dose F of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Part B (MAD): BIIB142 Cohort 3B

EXPERIMENTAL

Participants will receive Dose D of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state.

Drug: BIIB142; Drug: BIIB142-Matching Placebo

Interventions

BIIB142 DRUG

Administered Orally

Part A (SAD): BIIB142 Cohort 2A; Part A (SAD): BIIB142 Cohort 3A; Part A (SAD): BIIB142 Cohort 4A; Part A (SAD): BIIB142 Cohort 5A; Part A (SAD): BIIB142 Cohort 6A; Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A; Part B (MAD): BIIB142 Cohort 2B; Part B (MAD): BIIB142 Cohort 3B; Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B

BIIB142-Matching Placebo DRUG

Administered Orally

Part A (SAD): BIIB142 Cohort 2A; Part A (SAD): BIIB142 Cohort 3A; Part A (SAD): BIIB142 Cohort 4A; Part A (SAD): BIIB142 Cohort 5A; Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A; Part B (MAD): BIIB142 Cohort 2B; Part B (MAD): BIIB142 Cohort 3B; Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Have a body mass index between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, at screening.
• Weight ≥ 50 kilograms (kg) at screening.
• Negative polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in prior to randomization.
• Must be in good health as determined by the Investigator.

You may not qualify if:

• History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
• History of severe allergic or anaphylactic reactions
• History of or ongoing malignant disease (with limited exceptions)
• Systolic blood pressure \>150 millimeters of mercury (mmHg) or \<90 mmHg.
• Clinically significant (as determined by the Investigator) electrocardiogram (ECG) abnormalities.
• History of or positive test for human immunodeficiency virus (HIV).
• Chronic, recurrent, or serious infection within 90 days prior to Screening.
• Symptoms of bacterial, fungal, or viral infection within 14 days prior to Screening.
• Any live or attenuated immunization within 14 days prior to Screening.
• Use of prescription medications, over-the-counter medications that alter hepatic or renal clearance, or nutraceuticals within 28 days prior to Check-in.
• MAD Cohorts only: Suicidal ideation with some intent to act within 6 months prior to the start of Screening or history of suicidal behavior within one year prior to Screening.

Sponsors & Collaborators

• Biogen: lead

Study Sites (1)

PPD Development, LP

Las Vegas, Nevada, 89113, United States

RECRUITING

Study Officials

• Medical Director

  Biogen

  STUDY DIRECTOR

Central Study Contacts

US Biogen Clinical Trial Center

CONTACT

866-633-4636; clinicaltrials@biogen.com

Global Biogen Clinical Trial Center

CONTACT

clinicaltrials@biogen.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 14, 2025
• First Posted: August 21, 2025
• Study Start: August 29, 2025
• Primary Completion (Estimated): August 6, 2026
• Study Completion (Estimated): August 6, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

US (1)